The Risk of Breast, Endometrial and Ovarian Cancer in Users of Hormonal Preparations
- 16 March 2006
- journal article
- review article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 98 (3), 288-296
- https://doi.org/10.1111/j.1742-7843.2006.pto_277.x
Abstract
Because endogenous hormones play a major role in the risk of breast, endometrial and ovarian cancer, the impact on risk of oral contraceptives and of hormonal therapy given at about the time of menopause has been a major concern. Numerous studies provide insight into whether risk is increased or decreased in association with use of these preparations. Oral contraceptives present a chemopreventive opportunity for endometrial cancer and ovarian cancer as risk is dramatically lower among women who have used these preparations than among those who have not. Balanced against this is the potential for risk of breast cancer to be increased with oral contraceptive use. A pooled analysis of studies conducted through the early 1990s found that only current or recent users were at higher risk of breast cancer, but two more recent studies provide conflicting results with one showing no impact of oral contraceptives on risk of any group of women and the other showing an increase in risk with use. Among women participating in observational studies who are current or recent users of oestrogen therapy and who have relatively long durations of use, risk of breast cancer is modestly elevated; results from the Women's Health Initiative trial, based on a relatively short duration of oestrogen use are consistent with these observations. Oestrogen therapy increases endometrial cancer risk dramatically. It may also increase the risk of ovarian cancer; however more study of this issue is needed as the literature is inconsistent. Combined oestrogen and progestin therapy increases breast cancer risk by as much as 10% per year of use. Endometrial cancer risk is not elevated when combined therapy is given in a cyclic manner with progestin administered only part of the time and it is reduced when both oestrogen and progestin are administered on a daily basis. As with oestrogen therapy, the impact of combined therapy on ovarian cancer risk is uncertain.Keywords
This publication has 51 references indexed in Scilit:
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- The Power of the Pill: Oral Contraceptives and Women’s Career and Marriage DecisionsJournal of Political Economy, 2002
- Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? 1☆Journal of the Society for Gynecologic Investigation, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA)Cancer Causes & Control, 1994
- Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinomaInternational Journal of Cancer, 1991
- Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human DevelopmentPublished by American Medical Association (AMA) ,1987
- Decreased Risk of Endometrial Cancer among Oral-Contraceptive UsersNew England Journal of Medicine, 1980
- Incidence of Endometrial Cancer in Relation to the Use of Oral ContraceptivesNew England Journal of Medicine, 1980